Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.
about
Contemporary Treatment of Metastatic Renal Cell CarcinomaAxitinib in the treatment of renal cell carcinoma: patient selection and perspectivesBeyond evidence-based data: scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinomaChinese guidelines on the management of renal cell carcinoma (2015 edition)Sequence of treatment in locally advanced and metastatic renal cell carcinomaCurrent management and future directions in the treatment of advanced renal cell carcinoma-a latin american perspective: 10 years in reviewClinical experience with everolimus in the second-line treatment of advanced renal cell carcinomaClinical use of cabozantinib in the treatment of advanced kidney cancer: efficacy, safety, and patient selectionEndothelial Cell mTOR Complex-2 Regulates Sprouting AngiogenesisEfficacy and Safety of Sorafenib Therapy on Metastatic Renal Cell Carcinoma in Korean Patients: Results from a Retrospective Multicenter StudyRenal cell cancer: overview of the current therapeutic landscape.Phase I trial of sunitinib and temsirolimus in metastatic renal cell carcinoma.Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trialCorrelation of genomic alterations assessed by next-generation sequencing (NGS) of tumor tissue DNA and circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma (mRCC): potential clinical implicationsImplementation of an Interleukin-2 National Registry: an opportunity to improve cancer outcomesRisk of treatment-related deaths with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysis of 41 randomized controlled trials.Cabozantinib versus Everolimus in Advanced Renal-Cell CarcinomaSEOM clinical guidelines for the treatment of renal cell carcinoma.Immunologics and chemotherapeutics for renal cell carcinoma.Targeted treatments in advanced renal cell carcinoma: focus on axitinib.Optimal first-line and second-line treatments for metastatic renal cell carcinoma: current evidence.Comparative Effectiveness of Second-Line Targeted Therapies for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis of Real-World Observational StudiesEvaluation of second-line and subsequent targeted therapies in metastatic renal cell cancer (mRCC) patients treated with first-line cediranib.Everolimus in metastatic renal cell carcinoma after failure of initial anti-VEGF therapy: final results of a noninterventional study.A systematic review of the efficacy and safety experience reported for sorafenib in advanced renal cell carcinoma (RCC) in the post-approval setting.Comparing comparators: a look at control arms in kidney cancer studies over the years.Sunitinib re-challenge in advanced renal-cell carcinoma.Risk of treatment-related mortality with sorafenib in cancer patients: a meta-analysis of 20 randomly controlled trials : Risk of sorafenib-associated death.SOX9 was involved in TKIs resistance in renal cell carcinoma via Raf/MEK/ERK signaling pathway.Clinical experience with temsirolimus in the treatment of advanced renal cell carcinomaIncreased risk of severe infections in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysisAngiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma.A retrospective study of predictive factors for unexpectedly prolonged or shortened progression-free survival and overall survival among patients with metastatic renal cell carcinoma who received first-line targeted therapyPotential impact of mTOR inhibitors on cervical squamous cell carcinoma: A systematic review.Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: the largest multicenter retrospective analysis of survival and prognostic factors.Efficacy of sequential therapies with sorafenib-sunitinib versus sunitinib-sorafenib in metastatic renal cell carcinoma: A systematic review and meta-analysis.Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II TrialBEZ235: When Promising Science Meets Clinical RealityAxitinib after Sunitinib in Metastatic Renal Cancer: Preliminary Results from Italian "Real-World" SAX Study.Efficacy and Toxicity of Mammalian Target Rapamycin Inhibitors in Patients with Metastatic Renal Cell Carcinoma with Renal Insufficiency: The Korean Cancer Study Group GU 14-08.
P2860
Q26740594-41569147-3289-409D-B42D-3C7158886A7BQ26751341-E766183E-F125-4E15-B42D-93E2F3AA3BB4Q26766240-3B450D5B-D00C-4A7E-81A9-04F764114E11Q26772206-9B802659-3E22-41CA-8947-B9067ABEA063Q26773653-FC3D8A5B-E952-4AF1-8EBF-BA17E3169A08Q26774515-E0045688-1960-43C9-93CD-D1D1D88F5BC2Q26783514-9E519B6B-F560-4ADE-A2C7-0B6FD2294AF7Q28074834-6A35D4DA-15FC-47D4-AB8D-5FE312611161Q28547399-8D41EE06-FFD1-4ECC-8601-2E0C2694CFD6Q28547506-8001F25F-1D86-4AE0-B9BE-4EED2B88A15BQ30248354-B2184E29-59AA-4AF7-B1E8-07395E85207AQ33419097-705986F8-0A25-47A1-9896-936B14DAA39AQ33750154-301C75A9-D49E-461A-83B9-A97C2D6F90E5Q33779585-5048C6FC-1BE1-48F9-A03D-50781F48588AQ33909119-4595F5A0-5811-480F-A74C-DE9AE5EC7304Q34352627-E0A6A8FD-D8E6-4EB3-933D-26AFBF42A705Q34495684-8262FDCA-BE3B-4766-B3B1-E2D86AE90013Q34553411-00E6FBEB-9226-4075-AFD5-62FAD62CD58DQ34660154-BD633179-1710-4272-9C87-3D594C7E74EFQ34661185-E1C74838-F481-46BF-AE6B-B354F9C38CCEQ34666150-0A85E768-D0FD-460D-87DC-EB251E4C6E58Q34672506-EB0A35B1-D5F0-4385-B20C-EAE67F5F2D68Q34777424-6C82993A-358F-4E81-90B6-91EED5D6EB11Q35549876-131B7F06-D4B5-4F78-8CAD-A749B3CA3958Q35591889-3C06E8CD-F970-43CA-ABA9-AB620002208DQ35677657-2D023375-3182-4D67-9343-9E09EE57E8ABQ35678358-48512B26-324D-43F2-A498-0C211FEEC5D6Q35691234-BC1354FF-56FF-4468-98E6-A46867B9A66DQ35741056-41E736DE-1337-4483-A479-64C241AAB16BQ35797388-8B2F9CBC-D263-4FF5-9E81-48B96F7EAC5AQ36024704-C5C8122F-8C09-4902-99DA-29EF7A861BE5Q36051199-BD1A0F05-3D54-4C0B-8745-41F5E148543AQ36092829-3BDEC902-5876-4911-A1F6-DCA6821F9AF6Q36206239-0AE2B43B-18C3-4F49-97E5-1E48EBD5A381Q36241010-337B4556-1612-4E87-A4F1-3C6F385667A7Q36252946-EBBD5C40-D7F1-4006-8F5A-226609834C29Q36726204-D54804AB-D770-453B-A718-85040768BFA0Q37242369-0427872C-3348-4480-B6FD-40F195A30762Q37290050-BEC6A71E-4286-4183-9DC7-D574C92EC6E0Q37367458-D3633544-E63B-4C3D-B55C-3847CF6C5781
P2860
Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.
description
2013 nî lūn-bûn
@nan
2013 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Randomized phase III trial of ...... tastatic renal cell carcinoma.
@ast
Randomized phase III trial of ...... tastatic renal cell carcinoma.
@en
Randomized phase III trial of ...... tastatic renal cell carcinoma.
@nl
type
label
Randomized phase III trial of ...... tastatic renal cell carcinoma.
@ast
Randomized phase III trial of ...... tastatic renal cell carcinoma.
@en
Randomized phase III trial of ...... tastatic renal cell carcinoma.
@nl
prefLabel
Randomized phase III trial of ...... tastatic renal cell carcinoma.
@ast
Randomized phase III trial of ...... tastatic renal cell carcinoma.
@en
Randomized phase III trial of ...... tastatic renal cell carcinoma.
@nl
P2093
P2860
P50
P356
P1476
Randomized phase III trial of ...... etastatic renal cell carcinoma
@en
P2093
Andreas Niethammer
Bernard Escudier
Dongrui Ray Lu
Ho Yeong Lim
Kenneth B Pittman
Peggy Senico
Subramanian Hariharan
Thomas E Hutson
P2860
P304
P356
10.1200/JCO.2013.50.3961
P407
P577
2013-12-02T00:00:00Z